Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study

Circulation

Volumn 101, Issue 4, 2000, Pages 378-384

  White, M ^a   Yusuf, S ^a   McKelvie, R S ^a   Pericak, D ^a   Young, J ^a   Latini, R ^a   Pogue, J ^a   Burns, R J ^a   Probstfield, J ^a   Tsuyuki, R T ^a   Maggioni, A P ^a   Avezum A , Jr ^a   Rouleau, J L ^a  

^a Canadian Cardiovascular Project Office   (Canada)

Author keywords

Heart failure; Hormones; Receptors, adrenergic, beta; Ventricles

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIGOXIN; DIURETIC AGENT; ENALAPRIL; METOPROLOL; NEUROHORMONE; NITRATE; PLACEBO; RENIN;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED RELEASE FORMULATION; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034142256     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.4.378     Document Type: Article

References (25)

1. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
2. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 342:1441-1446.
3. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Three-year follow-up of patients randomised in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet. 1998;351:1180-1181.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
5. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moye L, Pfeffer M, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival And Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29:229-236.
6. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349: 375-380.
7. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J. 1997;18:560-565.
8. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
9. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
10. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
11. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, Wang Y, Pogue J, Teo KK, White M, Avezum A Jr, Latini R, Held P, Lindgren E, Probstfield J, for the RESOLVD Pilot Study Investigators. Combination neurohormonal blockade with ACE inhibitors, angiotensin II. antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997;13: 1166-1174.
12. Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab. 1970;30:682-685.
13. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989;161:562-567.
14. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentrations of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab. 1988;66:605-610.
15. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
16. Sandberg A, Ragnarsson G, Jonsson UE, Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR. Eur J Clin Pharmacol. 1988;33(suppl):S3-S7.
17. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 1988;33(suppl):S9-S14.
18. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
19. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94: 2817-2825.
20. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R. β-Blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-2441.
21. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806.
22. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
23. Currie PJ, Kelly MJ, McKenzie A, Harper RW, Lim YL, Federman J, Anderson ST, Pitt A. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. J Am Coll Cardiol. 1984;3: 203-209.
24. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH. β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens. 1999;12:451-459.
25. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32:1839-1844.